What the research found

The piece argues that while we frequently blame chronic inflammation for serious diseases, our ability to identify and measure it remains poorly defined. C-reactive protein (CRP) and its high-sensitivity variant (hs-CRP) are the most common blood markers used to track systemic inflammation, but they only measure one protein produced by the liver in response to inflammatory signals—they don't pinpoint where inflammation originates or what's driving it.

The author traces how hs-CRP gained prominence in clinical practice after studies showed it predicted cardiovascular events better than LDL cholesterol in certain populations. However, this remains a prognostic association rather than proof that lowering CRP itself improves outcomes. Importantly, elevated CRP can reflect dozens of different underlying conditions, many of which don't necessarily show up on standard inflammatory markers at all.

Why it matters for you

If you're tracking CRP or hs-CRP in MyKine, understanding what it actually tells you is critical. A high result doesn't diagnose anything—it's a signal that something is driving systemic inflammation, and identifying what requires looking elsewhere. The piece highlights several modifiable drivers relevant to your tracking: visceral fat accumulation (which affects inflammation more than subcutaneous fat), insulin resistance (measurable via HOMA-IR), sleep quality (obstructive sleep apnea is a known driver), smoking, and even dental health.

This also matters for how you interpret interventions. If you're using supplements, dietary changes, or other protocols aimed at "reducing inflammation," you need specific, measurable markers to know whether they're working. CRP alone is too blunt. Depending on your situation, other markers like MMP-9 or TGF-beta 1 might be more informative, particularly if you suspect autoimmune involvement. The takeaway: treat elevated CRP as a starting point for investigation, not a diagnosis.

Caveats

• The piece is opinion/commentary from a clinician, not original research
• No new data on effect sizes or intervention outcomes provided
• Autoimmune conditions listed are described prevalence-only; not systematically reviewed
• The discussion of hs-CRP's predictive value relies on older literature (trials from ~2008) without recent meta-analysis